Semaglutide Syringe Dosage: What the Clinical Evidence Tells Us

Wegovy (semaglutide) is a once-weekly subcutaneous injection licensed in the UK for weight management at doses up to 2.4 mg, and now up to 7.2 mg following MHRA approval in April 2026.
The dose is titrated by a prescriber in gradual steps, typically every four weeks; the starting dose of 0.25 mg is a tolerability step, not a weight-loss dose.
Each dose level has its own evidence base: STEP 1 trial data showed an average of around 15% body-weight reduction at the 2.4 mg maintenance dose over 68 weeks.
Semaglutide is a prescription-only medicine, a prescriber decides your dose after assessing your medical history, weight, and any other conditions or medicines you take.

Semaglutide's dosage schedule for weight management follows a carefully studied titration pathway, starting low and stepping upward over several months. The licensed syringe or pen doses range from 0.25 mg right through to 2.4 mg weekly — and, more recently, up to 7.2 mg — with each step informed by trial data rather than guesswork. Because semaglutide is a prescription-only medicine in the UK, the specific dose a person takes is always decided by a prescriber following a full clinical assessment, not by the individual themselves.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

How the semaglutide dosage schedule was shaped by clinical evidence

What the STEP 1 trial established about dose and weight loss

The dose schedule used in licensed Wegovy pens was not arrived at arbitrarily. The STEP 1 trial, published in the New England Journal of Medicine, studied 2.4 mg once-weekly semaglutide over 68 weeks in adults with obesity who did not have type 2 diabetes. Participants lost an average of around 15% of their body weight. That figure represents the maintenance dose, the endpoint of a structured titration, not a flat dose given from day one.

The titration pathway matters because the GI side effects of semaglutide (nausea, diarrhoea, indigestion, and stomach discomfort are the most common) tend to be sharpest when the dose rises. Moving up slowly gives the body time to adjust. The licensed steps for Wegovy are 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg, each held for roughly four weeks before the prescriber reviews whether to continue titrating. A useful minute-long habit: before each new pen, check the dose printed on the label matches what your prescriber recorded at your last review. Mismatches are rare but worth catching early.

In April 2026, the MHRA went further, approving a dedicated single-dose 7.2 mg Wegovy pen for adults with a BMI of 30 or above. Trial data at this higher dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results. The 7.2 mg pen is a maximum dose for those who have already completed the lower titration steps; 0.25 mg remains the starting point.

Why the 0.25 mg starting dose exists, and what it is not for

One of the most common points of confusion around semaglutide dosage is the purpose of the first few weeks. The 0.25 mg dose is there to let your system settle. It does not produce meaningful weight loss on its own, and that is by design. If you are curious about what 0.25 mg actually looks like when drawn in a syringe, our guide to reading 0.25 mg semaglutide on a syringe explains the markings in plain terms.

The prescriber's decision about whether to move from one step to the next is based on tolerability, not just the calendar. If nausea or vomiting at a given dose is still significant after four weeks, a prescriber may recommend staying at that level longer rather than pushing upward. This is one of several reasons the dosage schedule is personalised rather than uniform. The NHS semaglutide patient information page provides a clear overview of common side effects and what to watch for at each stage.

For a broader look at how Wegovy's full dose range fits together, the Wegovy doses overview walks through each step and what the clinical guidance says about them. There is also a practical semaglutide syringe dosage conversion chart that can help when switching between presentations.

Semaglutide dosage in context: what a prescriber weighs up

The dose written on your prescription reflects more than your starting BMI. A prescriber considers your full medical history, any other medicines you take, whether you have conditions such as a history of pancreatitis or certain thyroid problems, and how well you have tolerated each previous step. Under the licensed indication, Wegovy is appropriate for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure or sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

Semaglutide for weight management is not the same medicine as Ozempic, even though both contain semaglutide. Ozempic carries a UK licence for type 2 diabetes, at lower doses, and is not licensed for weight loss. The distinction matters because the dosage schedules and licensed indications differ entirely. If you have landed on this page wondering about semaglutide dosage more broadly, or specifically about the maximum semaglutide dose available in the UK, those pages go into more depth on each.

For context on what treatment costs privately in the UK, our Wegovy cost guide covers what is typically included in a private prescription price and what questions are worth asking any provider. When you are ready to talk through your specific situation, speak to our prescribers through a free consultation, a real clinician reads every assessment the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions